At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 243 enrolled
Drug / intervention
Risankizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa
In Brief
A Phase 2 clinical trial evaluating Risankizumab and Placebo for risankizumab for Hidradenitis Suppurativa. Completed, enrolled 243 participants across 59 sites in 8 countries.
Detailed Summary
The primary objective of this study is to assess the safety and efficacy of risankizumab 180 mg and 360 mg versus placebo for the treatment of signs and symptoms of moderate to severe hidradenitis suppurativa (HS) in adult participants diagnosed for at least one year before the Baseline visit.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa
CountriesAustralia, Canada, France, Germany, Japan, Netherlands, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartJun 2019
Primary CompletionFeb 2021
Study CompletionAug 2021
TodayJul 2026
First PostedApr 24, 2019
Enrollment StartJun 3, 2019
Primary CompletionFeb 2, 2021
Study CompletionAug 2, 2021
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 7.2 years ago
Interventions
Risankizumabdrug
Risankizumab is administered as a SC injection in pre-filled syringe (PFS)
Placebo for risankizumabdrug
Placebo for risankizumab is administered as a SC injection in PFS